Similar articles for PMID: 33020231

Year	Number of Results
2008	1
2009	2
2010	1
2011	1
2012	1
2013	3
2014	10
2015	6
2016	15
2017	14
2018	8
2019	21
2020	20
2021	19
2022	14
2023	4
2024	0

1

Poorly Differentiated Neuroendocrine Carcinoma of the Parotid Gland and Moderately Differentiated Hepatic Metastases: A Discordant Histopathology Clarified by Dual-Tracer PET/CT.

Sharma P, Basu S. Sharma P, et al. J Nucl Med Technol. 2021 Mar;49(1):86-88. doi: 10.2967/jnmt.120.251587. Epub 2020 Oct 5. J Nucl Med Technol. 2021. PMID: 33020231 Free article.

2

MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with ⁶⁸Ga-DOTATATE and ¹⁸F-FDG and Multimodality Anatomic Imaging in Metastatic Neuroendocrine Tumors of Unknown Primary in a PRRT Workup Setting.

Sampathirao N, Basu S. Sampathirao N, et al. J Nucl Med Technol. 2017 Mar;45(1):34-41. doi: 10.2967/jnmt.116.185777. Epub 2017 Feb 2. J Nucl Med Technol. 2017. PMID: 28154019 Free article.

3

Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.

Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, Mohmaduvesh M, Al-Harbi M, Belda M, Caplin ME, Toumpanakis C, Bomanji J. Panagiotidis E, et al. J Nucl Med. 2017 Jan;58(1):91-96. doi: 10.2967/jnumed.116.178095. Epub 2016 Aug 11. J Nucl Med. 2017. PMID: 27516446 Free article.

4

Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of ¹⁷⁷Lu-DOTATATE PRRT: Does In Vivo Molecular PET Perform Better from the Viewpoint of Prediction of Tumor Biology?

Adnan A, Basu S. Adnan A, et al. J Nucl Med Technol. 2022 Sep;50(3):248-255. doi: 10.2967/jnmt.121.261998. Epub 2021 Dec 7. J Nucl Med Technol. 2022. PMID: 34876476 Free article.

5

Grade 3 metastatic neuroendocrine neoplasms of two unusual primary sites with contrasting differentiation characteristics: Dual tracer positron emission tomography and computed tomography imaging (¹⁸F-fluorodeoxyglucose and ⁶⁸Ga-DOTATATE) correlates and their treatment implications.

Loharkar S, Basu S. Loharkar S, et al. World J Nucl Med. 2020 Sep 9;20(1):125-128. doi: 10.4103/wjnm.WJNM_67_20. eCollection 2021 Jan-Mar. World J Nucl Med. 2020. PMID: 33850504 Free PMC article.

6

The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact.

Hayes AR, Furtado O'Mahony L, Quigley AM, Gnanasegaran G, Caplin ME, Navalkissoor S, Toumpanakis C. Hayes AR, et al. Clin Nucl Med. 2022 Jan 1;47(1):26-35. doi: 10.1097/RLU.0000000000003937. Clin Nucl Med. 2022. PMID: 34874347

7

Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.

Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Thapa P, et al. Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547. Nucl Med Commun. 2016. PMID: 27243215

8

Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?

Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I. Has Simsek D, et al. J Nucl Med. 2014 Nov;55(11):1811-7. doi: 10.2967/jnumed.114.142224. Epub 2014 Oct 14. J Nucl Med. 2014. PMID: 25315243 Free article.

9

Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.

Jois B, Asopa R, Basu S. Jois B, et al. Clin Nucl Med. 2014 Jun;39(6):505-10. doi: 10.1097/RLU.0000000000000429. Clin Nucl Med. 2014. PMID: 24662668

10

A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.

Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB. Kayani I, et al. J Nucl Med. 2009 Dec;50(12):1927-32. doi: 10.2967/jnumed.109.066639. Epub 2009 Nov 12. J Nucl Med. 2009. PMID: 19910422 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

116 results

Results by year